Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).
Saved in:
| Title: | Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). |
|---|---|
| Authors: | Mandl A; Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Chen R; Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Das S; Vanderbilt University Medical Center, Nashville, TN, USA., Strosberg JR; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Kasi A; University of Kansas Cancer Center, Kansas City, KS, USA., Konda B; The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, OH, USA., Li D; City of Hope National Medical Center, Duarte, CA, USA., Burns TF; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Chauhan A; Sylvester Comprehensive Cancer Center, University of Miami, FL, USA., Ciombor KK; Vanderbilt University Medical Center, Nashville, TN, USA., Dayyani F; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA., Dorff T; City of Hope National Medical Center, Duarte, CA, USA., Ohr JP; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Patel BB; VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA., Sukrithan V; The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, OH, USA., Soares HP; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Chen K; Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Obstetrics and Gynecology, Detroit, MI, USA., Liu SV; Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Tesfaye AA; Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Carducci MA; Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Beumer JH; Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. |
| Source: | The oncologist [Oncologist] 2026 May 08; Vol. 31 (6). |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyag140 |
